GLP1R and metabolic dysfunction-associated steatohepatitis: More recently, research on this new GLP-1 analog has gradually expanded into other areas, including diabetes, chronic kidney disease, cardiovascular disease, NASH, and Alzheimer’s disease (Knudsen and Lau, 2019).